PVR and ovarian serous adenocarcinoma: A panel of 11 auto-antibodies (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) provided 45% sensitivity at 98% specificity for serous ovarian cancer [111].